- Company to participate in several upcoming partnering/investor forums as well as scientific and medical conferences
- First clinical data in glioblastoma with oral T-cell immunotherapy VXM01 to be presented at ASCO Annual Meeting
Basel (Switzerland) and Mannheim (Germany), May 3, 2017 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will participate in several upcoming events in May and June.
Swiss Biotech Day 2017
May 4, 2017
Jointly organized by Swiss Biotech, the Swiss Biotech Association and BIOCOM AG, Swiss Biotech Day is the key annual get-together of the Swiss biopharmaceutical industry. Click here for more information about this event. Dr. Matthias Schroff, Chief Executive Officer of VAXIMM, will attend this industry event.
American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting
May 10-13, 2017
Washington, DC, USA
Dr. Sébastien Wieckowski, Senior Scientist at VAXIMM, will give a presentation entitled, “Non-Clinical Safety, Immunogenicity and Antitumor Efficacy of Live Attenuated Salmonella Typhimurium-Based Oral T-Cell Vaccines VXM01m, VXM04m and VXM06m,” on Saturday, May 13th, 10:15-10:30 AM in the Maryland ABC room at the Marriott Wardman Park Hotel. The abstract is available here.
May 22-23, 2017
Dr. Matthias Schroff will give a corporate presentation on Tuesday, May 23rd at 2 PM. Bio€quity, which is hosted by BioCentury, is an important European industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital and for pharmaceutical licensing professionals to assess top prospects. More information on this conference is available here.
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2-6, 2017
Chicago, IL, USA
Clinical data in glioblastoma with VAXIMM’s VXM01 oral T-cell immunotherapy will be presented in a poster entitled, “VXM01 phase I study in patients with operable progression of a glioblastoma.” The poster will be presented during the Central Nervous System Tumors Session on Sunday, June 5th, 1:15-4:45 PM. The abstract will be available online on May 17 at 5 PM EDT at http://abstracts.asco.org.
BIO International Convention
June 19-22, 2017
San Diego, CA, USA
VAXIMM will participate in one-on-one meetings at this event, which is hosted by the Biotechnology Innovation Organization (BIO). The convention is a major networking and education event with over 1,500 sessions and over 16,000 attendees from 76 countries. Click here for more information about this event.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. VAXIMM’s lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM’s investors include BB Biotech Ventures, Merck Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s clinical operations. For more information, please see www.vaximm.com.
Dr. Matthias Schroff
Tel.: +49 621 8359 687 0
MC Services AG
Tel: +49 89 210228 0